Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.

Philip C. Mack,Neal Goodwin,William S. Holland,Karen Kelly,Primo N. Lara,David R. Gandara

Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.

2013

Philip C. Mack
Neal Goodwin
William S. Holland
Karen Kelly
Primo N. Lara
David R. Gandara

8110 Background: The UC Davis - Jackson Labs Consortium has established a PDX resource of over 50 NSCLC models (12 EGFR mutant) for experimental therapeutics and personalized medicine, using the NS...

Keywords:

Cetuximab
Afatinib
Erlotinib
Cancer research
Patient Derived Xenograft
Medicine
Jackson Labs
Pathology
Personalized medicine
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations